An increasing volume of prostate biopsies and a worldwide shortage of urological pathologists puts a strain on pathology departments. Additionally, the high intra-observer and inter-observer variability in grading can result in overtreatment and undertreatment of prostate cancer. To alleviate these problems, we aimed to develop an artificial intelligence (AI) system with clinically acceptable accuracy for prostate cancer detection, localisation, and Gleason grading. Here we show examples of full-resolution digitized biopsies and corresponding AI-based grading.

More information is available in this publication:
P. Ström, K. Kartasalo, H. Olsson, L. Solorzano et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. The Lancet Oncology, Volume 21, Issue 2, 2020, Pages 222-232, ISSN 1470-2045, doi: 10.1016/S1470-2045(19)30738-7, url: https://www.sciencedirect.com/science/article/pii/S1470204519307387

An overview of all sample datasets can be found here: Prostate cancer in biopsies